During the last three months, 18 analysts shared their evaluations of Regeneron Pharmaceuticals (NASDAQ:REGN), revealing diverse outlooks from bullish to bearish. The table below offers a ...

Biotech company Regeneron (NASDAQ:REGN) reported Q4 CY2024 results , with sales up 10.3% year on year to $3.79 billion. Its ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and ...

About Regeneron Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents, develops and commercializes life-transforming medicines for people with serious diseases. Founded and led ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $71.75 billion, has been navigating a complex landscape of opportunities and challenges in recent months. According to ...

The upcoming report from Regeneron (REGN) is expected to reveal quarterly earnings of $11.60 per share, indicating a decline of 2.2% compared to the year-ago period. Analysts forecast revenues of ...

Wall Street expects a year-over-year decline in earnings on higher revenues when Regeneron (REGN) reports results for the quarter ended December 2024. While this widely-known consensus outlook is ...

We recently published a list of the 10 Best Cancer Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Clearly, options traders are pricing in a big move for Regeneron Pharmaceuticals shares, but what is the fundamental picture for the company? Currently, Regeneron Pharmaceuticals is a Zacks Rank ...

Regeneron Science Talent Search alumni have ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Sign up for our newsletter to get the latest on the transformative ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Investors in Regeneron Pharmaceuticals, Inc. (Symbol: REGN) saw new options begin trading this week, for the March 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up ...